Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVBrasil
NCT01310738Phase 4Terminated
- Sponsor
- University of Brasília
- Start
- Feb 2011
- Primary completion
- Oct 2014
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liposomal amphotericin b, amphotericin b deoxycholate and meglumine antimoniate in visceral leishmaniasis (VL) (4 arms), sponsored by University of Brasília. Primary endpoint: Cure rate at 6 months. Started Feb 2011; status: terminated.
02
Drugs
liposomal amphotericin bamphotericin b deoxycholatemeglumine antimoniate
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT01310738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310738.